Zendal Health

Zendal is a Spanish biopharmaceutical group focused on the research, development, and manufacture of vaccines and biologics for human and animal health. The company operates as a major international player in the vaccine industry, notably through its subsidiary Biofabri, which is developing MTBVAC, the first live-attenuated vaccine against tuberculosis to reach Phase 3 trials. In addition to its proprietary pipeline, Zendal is a prominent Contract Development and Manufacturing Organization (CDMO), offering comprehensive services from process development to industrial-scale production. Their facilities are equipped for complex biological processes, including viral and bacterial vaccine production and fill-and-finish operations. The group maintains a strong global presence, exporting products to over 65 countries and collaborating with major international health organizations.